Skip to main content

Table 1 Patient characteristics

From: Accuracy evaluation of mainstream and sidestream end-tidal carbon dioxide monitoring during noninvasive ventilation: a randomized crossover trial (MASCAT-NIV trial)

 

Included patients

N = 60

Age, mean (SD), years

70.7 (11.2)

Male, n (%)

37 (61.7)

Body mass index, mean (SD), kg/m2

24.9 (4.0)

Patient category

 

 Non-scheduled surgery, n (%)

16 (26.7)

 Scheduled surgery, n (%)

23 (38.3)

 Medical, n (%)

21 (35.0)

APACHE II score, median (IQR), points*

19 (14–25)

SOFA score, median (IQR), points*

8 (7–11.5)

Updated Charlson comorbidity index, median (IQR), points

3 (2–4)

 Chronic heart failure, n (%)

40 (66.7)

 Chronic respiratory failure, n (%)

8 (1.3)

 Renal disease, n (%)

35 (58.3)

Mechanical ventilation duration, days†

2 (2–4)

Weaning category

 

 Short weaning, n (%)

50 (83.3)

 Difficult weaning, n (%)

10 (16.7)

 Prolonged weaning, n (%)

0 (0)

Glasgow Coma Scale, median (IQR), points†

14 (13–15)

Vasoactive drugs use, n (%)

32 (53.3)

Nasal gastric tube placement, n (%)

40 (66.7)

Reintubation within ICU stay, n (%)

3 (5.0)

Length of ICU stay, days

4 (3–8)

Length of hospitalization§, days

33 (23.5–41)

ICU mortality, n (%)

0 (0)

Hospital mortality, n (%)

10 (16.7)

  1. APACHE II, Acute Physiology and Chronic Health Evaluation II; ICU, Intensive Care Unit; SOFA, Sequential Organ Failure Assessment
  2. *At ICU admission
  3. At the day of extubation
  4. Defined by the WIND criteria
  5. §Excluded 10 patients who died